Market Reactions to Drug Developments and Corporate Earnings

This chapter explores the surge in stock prices for pharmaceutical giants Nova Nordisk and Eli Lilly due to advancements in obesity treatments, alongside Intel's substantial investment in the U.S. chip sector under the Chips Act. It contrasts these developments with the financial performances of Dick's Sporting Goods and Best Buy, revealing differing outcomes in the retail landscape.